Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07653685CT.gov A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07281768CT.gov Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07622550CT.gov A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance | — | Not Yet Recruiting | — | — | — |
NCT07381309CT.gov Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM | — | Not Yet Recruiting | — | — | — |
NCT07570914CT.gov Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT07462143CT.gov A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07551778CT.gov Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07503756CT.gov JS212 Combination Therapies in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07094893CT.gov Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status | — | Not Yet Recruiting | — | — | — |
NCT07412613CT.gov Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer | — | Recruiting | — | — | — |
Show 226 more trialsShow fewer
NCT07365592CT.gov Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC | — | Recruiting | — | — | — |
NCT07503639CT.gov Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07448142CT.gov Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT07229846CT.gov A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | — | Not Yet Recruiting | — | — | — |
NCT07395063CT.gov A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. | — | Not Yet Recruiting | — | — | — |
NCT07243938CT.gov Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) | — | Not Yet Recruiting | — | — | — |
NCT07221357CT.gov A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07283367CT.gov A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. | — | Recruiting | — | — | — |
NCT07268677CT.gov A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis. | — | Not Yet Recruiting | — | — | — |
NCT07233850CT.gov A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | — | Not Yet Recruiting | — | — | — |
NCT07407465CT.gov Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | — | Recruiting | — | — | — |
NCT07215936CT.gov Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen | — | Active Not Recruiting | — | — | — |
NCT07284992CT.gov SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC | — | Recruiting | — | — | — |
NCT07334587CT.gov Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma | — | Enrolling By Invitation | — | — | — |
NCT07134101CT.gov Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01) | — | Not Yet Recruiting | — | — | — |
NCT07154316CT.gov Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT07051785CT.gov Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07025239CT.gov QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07020221CT.gov A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT06963502CT.gov A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06885385CT.gov A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer | — | Recruiting | — | — | — |
NCT06899477CT.gov Pre-Operative Treatment in REseCTable COlon CanceR | — | Not Yet Recruiting | — | — | — |
NCT06949982CT.gov Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes | — | Recruiting | — | — | — |
NCT06848465CT.gov LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis | — | Recruiting | — | — | — |
NCT06835179CT.gov SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. | — | Not Yet Recruiting | — | — | — |
NCT06475352CT.gov Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme | — | Recruiting | — | — | — |
NCT06621563CT.gov Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06090994CT.gov Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy | — | Recruiting | — | — | — |
NCT06825624CT.gov ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06596343CT.gov Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06616259CT.gov First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study | — | Not Yet Recruiting | — | — | — |
NCT06493760CT.gov A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | — | Recruiting | — | — | — |
NCT06550453CT.gov Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06425133CT.gov Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers | — | Recruiting | — | — | — |
NCT06504901CT.gov Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT06275958CT.gov DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06324357CT.gov Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | — | Recruiting | — | — | — |
NCT06881537CT.gov CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer | — | Recruiting | — | — | — |
NCT06328738CT.gov ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06405139CT.gov Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06192680CT.gov Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06253871CT.gov A Phase 1/1b Study of IAM1363 in HER2 Cancers | — | Recruiting | — | — | — |
NCT06566755CT.gov Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer | — | Recruiting | — | — | — |
NCT06765616CT.gov Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT05803382CT.gov Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | — | Recruiting | — | — | — |
NCT06099951CT.gov Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy | — | Not Yet Recruiting | — | — | — |
NCT06120127CT.gov Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence | — | Unknown | — | — | — |
NCT05985707CT.gov KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT05954078CT.gov Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer | — | Recruiting | — | — | — |
NCT05970302CT.gov XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC | — | Recruiting | — | — | — |
NCT06516445CT.gov SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC | — | Recruiting | — | — | — |
NCT05555901CT.gov The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05462613CT.gov Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05585814CT.gov CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT05861505CT.gov COLLISION RELAPSE Trial | — | Recruiting | — | — | — |
NCT05652894CT.gov A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05775900CT.gov Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT05609370CT.gov A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05659290CT.gov Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06048146CT.gov A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis | — | Completed | — | — | — |
NCT05489211CT.gov Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | — | Recruiting | — | — | — |
NCT05464030CT.gov Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | — | Recruiting | — | — | — |
NCT05451719CT.gov Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy | — | Unknown | — | — | — |
NCT05382442CT.gov A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05353582CT.gov Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | — | Unknown | — | — | — |
NCT05544812CT.gov A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT05016869CT.gov Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05327751CT.gov Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer | — | Unknown | — | — | — |
NCT05091528CT.gov A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | — | Terminated | — | — | — |
NCT05171660CT.gov Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05200299CT.gov mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer | — | Unknown | — | — | — |
NCT04866108CT.gov A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy | — | Unknown | — | — | — |
NCT05008809CT.gov Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) | — | Recruiting | — | — | — |
NCT05068206CT.gov A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx | — | Unknown | — | — | — |
NCT04262635CT.gov Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05074966CT.gov The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts | — | Unknown | — | — | — |
NCT05093907CT.gov A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05022030CT.gov First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes | — | Unknown | — | — | — |
NCT04854668CT.gov A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT06206096CT.gov PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC | — | Unknown | — | — | — |
NCT04733963CT.gov Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04753203CT.gov Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients | — | Unknown | — | — | — |
NCT04194359CT.gov Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06547385CT.gov Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04534218CT.gov Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT04659382CT.gov Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04108481CT.gov Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT04456699CT.gov Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | — | Completed | — | — | — |
NCT04301557CT.gov PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03228043CT.gov Apatinib for Resectable Colorectal Cancer | — | Withdrawn | — | — | — |
NCT04227041CT.gov A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer | — | Unknown | — | — | — |
NCT04080843CT.gov Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients | — | Completed | — | — | — |
NCT04304209CT.gov Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04324476CT.gov A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04160416CT.gov mXELOXIRI Combined With Molecular Targeted Drug in mCRC | — | Unknown | — | — | — |
NCT04008511CT.gov Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT03828227CT.gov QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. | — | Active Not Recruiting | — | — | — |
NCT03984578CT.gov Window of Opportunity Study in Colorectal Cancer | — | Completed | — | — | — |
NCT03950154CT.gov Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT03854799CT.gov Immunotherapy In Locally Advanced Rectal Cancer | — | Completed | — | — | — |
NCT03869892CT.gov Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. | — | Active Not Recruiting | — | — | — |
NCT03775525CT.gov Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | — | Unknown | — | — | — |
NCT03813641CT.gov RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study) | — | Unknown | — | — | — |
NCT03307603CT.gov Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer | — | Withdrawn | — | — | — |
NCT03645876CT.gov SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT03564912CT.gov Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC | — | Completed | — | — | — |
NCT03376659CT.gov Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT03169777CT.gov QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | — | Withdrawn | — | — | — |
NCT03686254CT.gov The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM | — | Unknown | — | — | — |
NCT03565029CT.gov Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer | — | Completed | — | — | — |
NCT03457896CT.gov Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | — | Unknown | — | — | — |
NCT03396926CT.gov Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer | — | Completed | — | — | — |
NCT03117972CT.gov Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | — | Terminated | — | — | — |
NCT02873195CT.gov Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03185988CT.gov Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | — | Unknown | — | — | — |
NCT02758951CT.gov Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | — | Active Not Recruiting | — | — | — |
NCT03132025CT.gov Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT03050814CT.gov Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | — | Terminated | — | — | — |
NCT03504618CT.gov Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI | — | Completed | — | — | — |
NCT02955940CT.gov An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | — | Active Not Recruiting | — | — | — |
NCT02861300CT.gov CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | — | Completed | — | — | — |
NCT02743221CT.gov A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy | — | Completed | — | — | — |
NCT02575378CT.gov Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT02291289CT.gov A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT02934529CT.gov Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | — | Completed | — | — | — |
NCT02280694CT.gov Low Dose Metronomic Poly-chemotherapy for Metastatic CRC | — | Completed | — | — | — |
NCT02415829CT.gov Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients | — | Unknown | — | — | — |
NCT02251977CT.gov Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer | — | Completed | — | — | — |
NCT02128425CT.gov FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT02083653CT.gov Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02688023CT.gov Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer | — | Unknown | — | — | — |
NCT02068131CT.gov Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT01960023CT.gov Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT02210364CT.gov Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). | — | Completed | — | — | — |
NCT01718808CT.gov Cetuximab for Elderly Patients With mCRC | — | Terminated | — | — | — |
NCT01705002CT.gov Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | — | Completed | — | — | — |
NCT01661972CT.gov Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01506167CT.gov An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) | — | Completed | — | — | — |
NCT01898104CT.gov Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer | — | Unknown | — | — | — |
NCT01776307CT.gov A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT02271464CT.gov Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01531595CT.gov Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT01472770CT.gov A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02720926CT.gov Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer | — | Terminated | — | — | — |
NCT01328171CT.gov FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) | — | Completed | — | — | — |
NCT01322152CT.gov Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01293942CT.gov IXO+A in mCRC With Liver-only Metastases | — | Withdrawn | — | — | — |
NCT01229813CT.gov Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT01167725CT.gov Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | — | Terminated | — | — | — |
NCT01193517CT.gov Azacitidine and CAPOX in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01097018CT.gov Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01280643CT.gov Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01071655CT.gov Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00997685CT.gov Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC) | — | Unknown | — | — | — |
NCT01067053CT.gov Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. | — | Unknown | — | — | — |
NCT00959946CT.gov Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00954876CT.gov Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer | — | Withdrawn | — | — | — |
NCT00961571CT.gov Sunitinib and Capecitabine for First Line Colon Cancer | — | Terminated | — | — | — |
NCT01077739CT.gov A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin | — | Completed | — | — | — |
NCT00920868CT.gov XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | — | Completed | — | — | — |
NCT00875771CT.gov Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients | — | Completed | — | — | — |
NCT00869570CT.gov External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer | — | Completed | — | — | — |
NCT00853684CT.gov Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT00686166CT.gov S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer | — | Completed | — | — | — |
NCT01311050CT.gov A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT00777478CT.gov Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer | — | Unknown | — | — | — |
NCT00755534CT.gov Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC | — | Terminated | — | — | — |
NCT00796718CT.gov A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer | — | Completed | — | — | — |
NCT00700570CT.gov A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00677443CT.gov Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00642603CT.gov A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00784446CT.gov First-line Therapy of Stage IV Colorectal Cancer | — | Completed | — | — | — |
NCT01310985CT.gov A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer | — | Completed | — | — | — |
NCT00577031CT.gov OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. | — | Completed | — | — | — |
NCT00551213CT.gov A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) | — | Completed | — | — | — |
NCT00531115CT.gov Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. | — | Terminated | — | — | — |
NCT00541112CT.gov Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT00574171CT.gov Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma | — | Completed | — | — | — |
NCT00640081CT.gov Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00502671CT.gov A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer. | — | Completed | — | — | — |
NCT00482222CT.gov Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer | — | Unknown | — | — | — |
NCT01135498CT.gov A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00396487CT.gov Tailored Treatment in Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00399035CT.gov Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00514761CT.gov Phase II Efficacy Study of AZD6244 in Colorectal Cancer | — | Completed | — | — | — |
NCT00349336CT.gov A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00532909CT.gov Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00251186CT.gov First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients | — | Terminated | — | — | — |
NCT00305643CT.gov Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer | — | Terminated | — | — | — |
NCT01159171CT.gov A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. | — | Completed | — | — | — |
NCT00290615CT.gov Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00268463CT.gov Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer | — | Terminated | — | — | — |
NCT00905047CT.gov Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01227707CT.gov A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer. | — | Completed | — | — | — |
NCT00383695CT.gov Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | — | Unknown | — | — | — |
NCT00538291CT.gov Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment | — | Terminated | — | — | — |
NCT00353262CT.gov A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT01131078CT.gov A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum | — | Completed | — | — | — |
NCT00294359CT.gov The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00208546CT.gov Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00182715CT.gov Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT00107250CT.gov AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07) | — | Completed | — | — | — |
NCT00081224CT.gov Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum | — | Terminated | — | — | — |
NCT00254137CT.gov Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00070434CT.gov S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum | — | Withdrawn | — | — | — |
NCT00444678CT.gov Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00459901CT.gov Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00227734CT.gov Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00226941CT.gov A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer | — | Terminated | — | — | — |
NCT00159445CT.gov Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00242788CT.gov IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure | — | Completed | — | — | — |
NCT01196260CT.gov Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III | — | Unknown | — | — | — |
NCT00087334CT.gov Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00819754CT.gov A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00069095CT.gov A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00069108CT.gov A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00230399CT.gov Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00064181CT.gov Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00123851CT.gov Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00312000CT.gov Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma | — | Completed | — | — | — |
NCT00183833CT.gov Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00258232CT.gov Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01219920CT.gov FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00048139CT.gov A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00048126CT.gov A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00009737CT.gov A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Approved | BB · 67 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →